Protein Tyrosine Kinases

6-Hydroxy-2,2′,4,4′-tetrabromodiphenyl ether is a selective inhibitor of Tie2 kinase, exhibiting an IC50 value of 2.1 μM. This compound interacts with the ATP binding site of Tie2, effectively inhibiting its kinase activity and thereby blocking tumor angiogenesis. It is a valuable tool for research focused on vascular biology and cancer therapeutics.

Vasculotide is a Tie-2 activator that mimics angiopoietin-1, inducing phosphorylation of the Tie-2 receptor. It exhibits anti-inflammatory properties and reduces vascular permeability, making it effective in ameliorating endotoxin-induced endothelial barrier dysfunction. Research applications include promoting angiogenesis in diabetic ulcer models and protecting against vascular leakage in murine abdominal sepsis, while also improving microcirculatory perfusion in rat models of hemorrhagic shock.

Trebananib is an Fc fusion peptibody that selectively neutralizes angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2) by inhibiting their interaction with the TIE2 receptor. This mechanism leads to significant anti-angiogenic and anti-tumor effects, making Trebananib a valuable tool for research in cancer biology and vascular studies. Its ability to modulate angiogenesis provides important insights for therapeutic strategies targeting tumor vasculature.

Tie2 kinase inhibitor 2 is a selective inhibitor of the Tie2 kinase with an IC50 value of 1 μM. It effectively inhibits endothelial cell tube formation, making it a valuable tool for investigating Tie2-mediated angiogenic disorders. This compound is suitable for research focused on angiogenesis and related therapeutic applications.

Tie2 Kinase Inhibitor 3 is a potent inhibitor of the Tie-2 kinase, exhibiting an IC50 value of 30 nM. By competing with the ATP binding site of Tie-2, this compound effectively inhibits phosphorylation and signaling pathways associated with Tie-2, thereby influencing the stability and maturation of blood vessels. Its mechanisms provide valuable insights into tumor angiogenesis, making Tie2 kinase inhibitor 3 a significant tool for research focused on restricting tumor growth and modulating angiogenic processes.

BSF-466895 is a potent Tie2 inhibitor with an IC50 value of 5 nM, demonstrating significant inhibition of Tie1 as well. This compound is valuable for research applications focused on vascular biology and angiogenesis, as well as exploring the therapeutic potential in disorders related to angiogenic dysregulation. BSF-466895 serves as a useful tool for elucidating the role of the Tie2 signaling pathway in various biological contexts.

A 83-01 sodium is a selective inhibitor of the transforming growth factor-beta (TGF-β) type I receptors ALK4, ALK5, and ALK7. With IC50 values of 12 nM, 45 nM, and 7.5 nM, it effectively blocks transcriptional activity induced by these kinases. This compound is valuable for research applications focused on TGF-β signaling pathways and regulation of cellular processes such as proliferation, differentiation, and epithelial-mesenchymal transition.

M4K-2009 is a potent inhibitor of ALK2, exhibiting an IC50 value of 13 nM, and is capable of penetrating the blood-brain barrier. In addition to its primary activity against ALK2, M4K-2009 demonstrates efficacy against the hERG potassium channel. This compound is valuable for research in the areas of bone morphogenetic protein signaling and related therapeutic applications.

SI-2 hydrochloride is a potent inhibitor of SRC-3, a transcription co-regulator involved in various signaling pathways. This compound displays favorable pharmacokinetic properties and reduced toxicity, making it suitable for in vivo studies. SI-2 hydrochloride is valuable for research related to cancer biology, endocrine signaling, and other conditions where SRC-3 plays a critical role.

(+)−Theta-cypermethrin is a stereoisomer of cypermethrin that functions as a selective binder to AKT1, SRC, STAT3, and epidermal growth factor receptor (EGFR). This compound is known to penetrate the blood-brain barrier, leading to alterations in the amplitude of delayed rectifier potassium channel currents and significant shifts in the activation and inactivation curves at elevated concentrations. Additionally, (+)-Theta-cypermethrin induces abnormal electrical activity in rat hippocampal neurons and is associated with chronic respiratory system damage and neurotoxicity. It serves as a valuable tool for research into signal transduction pathways and neuropharmacology.

TRI-611 is an orally active molecular glue degrader that targets the anaplastic lymphoma kinase (ALK). It forms a ternary complex with the substrate receptor CRBN, leading to polyubiquitination and subsequent degradation of ALK, including resistant fusion proteins. TRI-611 effectively inhibits ALK-mediated downstream signaling and exhibits anti-proliferative effects in ALK-positive cancer cells. Preclinical studies demonstrate its capability to induce regression of ALK-positive non-small cell lung cancer tumors, making it a valuable tool for research into TKI-refractory tumors and central nervous system metastases.

Cyclo[K(N3)larllt] is a cyclic peptide that specifically targets the epidermal growth factor receptor (EGFR) with a Kd value of 5.09 μM and demonstrates selectivity for related proteins HER2 and HER3. This compound exhibits no cytotoxicity and does not inhibit the growth of EGFR-overexpressing cancer cells. Cyclo[K(N3)larllt] is ideal for use as a ligand in EGFR-targeted fluorescent conjugates, facilitating the detection of tumors with elevated EGFR levels. Its applications extend to research focused on colorectal cancer and related pathologies.

PF-07245303 is an ITK/TRK inhibitor that effectively reduces the production of pro-inflammatory cytokines such as IL-4 and IFNγ. This compound inhibits the phosphorylation of PLCγ1 and disrupts nerve growth factor-induced basophil activation and TRKA phosphorylation. Additionally, PF-07245303 demonstrates a reduction in oxazolone-induced ear swelling in mouse models, making it a valuable tool for research into atopic dermatitis and related inflammatory conditions.

Peptide HRH is a polypeptide that specifically targets vascular endothelial growth factor receptors (VEGFR). It effectively inhibits VEGF-stimulated endothelial cell proliferation, thereby disrupting angiogenesis. Additionally, Peptide HRH demonstrates efficacy in suppressing corneal neovascularization. This peptide is suitable for research applications focused on anti-angiogenesis and related studies.

VEGFR2-IN-84 is a potent VEGFR2 inhibitor that operates as a multi-targeted tyrosine kinase inhibitor utilizing a naphthalene ring scaffold. It exhibits sub-nanomolar affinity for VEGFR2 and effectively inhibits other kinases, including Kit, FGFR, PDGFR, and Ret. By competitively binding to the ATP-binding pocket, VEGFR2-IN-84 disrupts the phosphorylation of VEGFR2, leading to significant reduction in endothelial cell proliferation, migration, and tumor angiogenesis. This compound demonstrates broad antiproliferative activity against various solid tumors, such as liver, lung, and renal cancers, while exhibiting low toxicity to normal cells. VEGFR2-IN-84 is suitable for research applications focused on malignant tumors.

ZW-49 is a potent orally active pan-EGFR inhibitor, demonstrating IC50 values ranging from 0.03 to 1.5 nM. This compound selectively targets various EGFR mutations while sparing wild-type EGFR and other familial targets, effectively blocking the ATP-binding pocket and a conserved hydrophobic subpocket without causing steric conflicts with PACC mutation P loops. ZW-49 exhibits significant anti-proliferative activity by inhibiting cancer cell proliferation, inducing G0/G1 phase cell-cycle arrest, and promoting apoptosis, making it a valuable reagent for cancer research, particularly in non-small cell lung cancer models.

Rinumafusp alfa is a human monoclonal antibody that specifically inhibits the epidermal growth factor receptor (EGFR) by targeting ERBB3/HER3. This compound demonstrates potential in blocking tumor cell signaling pathways, thereby impeding tumor growth and progression. It is primarily utilized in research applications focused on cancer biology and therapeutic development targeting EGFR-related pathways.

FLT3-IN-40 is a type I ATP-competitive inhibitor of FLT3, demonstrating an IC50 of 16.26 nM. This compound effectively reduces FLT3 autophosphorylation and downregulates ERK phosphorylation, thereby exhibiting significant antiproliferative activity, influencing cell cycle regulation, and promoting apoptosis. FLT3-IN-40 is particularly valuable for research applications focused on acute myeloid leukemia.

PSP-0119 is a highly selective PROTAC degrader targeting IRAK4, demonstrating an IC50 of 2.83 nM. This compound effectively inhibits IRAK4 kinase activity, NF-κB signaling, and IL-1β-induced IRAK4 phosphorylation. Notably, PSP-0119 induces degradation of IRAK4 specifically in FLT3-mutant acute myeloid leukemia (AML) cell lines while sparing FLT3-wild-type AML cells and normal bone marrow. It serves as a valuable tool for research into the mechanisms underlying AML, particularly in targeting aberrant IRAK4 activity.

TG 100948 is a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and tyrosine kinase Src. This compound demonstrates significant biological activity by reducing retinal edema and retinal thickening, as well as eliminating bullous edema cysts in rat models of ischemic retinal vein occlusion. TG 100948 is valuable for research into the pathophysiology and potential treatments of ischemic retinal vein occlusion.